tbuckley/cabot-search huggingface dataset:
Impact of information sources on expectation of cancer treatment side effects: A URCC CCOP study
Authors: M. Hofman, J. A. Roscoe, J. T. Hickok, G. R. Morrow, D. F. Moore, J. L. Wade, T. Fitch
Journal: Journal of Clinical Oncology (2004)

8094 Background: Cancer patients can expect many side effects from their chemotherapy or radiation treatment. This study investigated possible causes of these expectations. Methods: 1015 Cancer patients from 17 Community Clinical Oncology Program (CCOP) institutions affiliated with the University of Rochester CCOP research base were surveyed for symptoms they expected from treatment (given 12 common symptoms); the symptoms they were already experiencing; their age, education, disease site and gender; Karnofsky score; self-rated general health; and which of 25 sources of cancer information grouped into 3 broad areas of medical (10), community (7) and media (8) they have used. Results: 3 significant predictors (p<.05) of the number of side effects expected by the patients emerged from a stepwise multiple regression: the number of side effects the patient was already experiencing (Δr2=0.14), patient age (Δr2=0.05) and the number of information sources used (Δr2=0.03). Only the cancer care physician, the PCP (primary care physician) and newspapers had a negative correlation with individual side effects (PCP and newspapers related to a lower expectancy of hair loss, p<0.05) all other information sources had none or a positive correlation with the expectancy of a side effect. The total number of expected side effects was most highly related (all p<0.01) to using the Internet (r=0.20) the American Cancer Society (r=0.19) and the NCI (National Cancer Institute, r=0.18) as sources of treatment information. Use of information sources from the NCI was positively associated with expecting every side effect (9 with p<0.01, 3 with p<0.05). Conclusions: Information sources can have an impact on the expectancy of side effects by people undergoing cancer treatment. Since this expectancy may influence the actual experience of the patient during the treatment, knowing how many and which sources of information patients have used may promote optimal management of treatment related symptoms. Supported, in part, by a supplement from the Division of Cancer Control and Population Sciences, NCI, to Public Health Service grant U10 CA37420 and by grant RSG-01-071-PBP from the ACS. No significant financial relationships to disclose.
Effect of xamoterol on myocardial energetics in man.
Authors: Osamu Sakai, Masatoshi Fujita, Shigetake Sasayama, Hidetsugu Asanoi, Hisayoshi Nakajima, Higeru Yokawa
Journal: Circulation (1988)

We analyzed the effect of xamoterol (beta 1-partial agonist) on myocardial energetics in 8 patients with normal left ventricular function. We measured resting systemic and coronary hemodynamics before and after a single intravenous injection of xamoterol (0.1 mg/kg). This agent increased heart rate from 70 +/- 7 to 80 +/- 11 beats/min (p less than 0.05) and cardiac index from 2.9 +/- 0.5 to 3.2 +/- 0.5 L/min.m2 (p less than 0.01), respectively. Left ventricular peak positive dp/dt (1870 +/- 350 vs 2620 +/- 580 mmHg/sec (p less than 0.01) and left ventricular ejection fraction (62 +/- 7 vs 70 +/- 7% (p less than 0.01] also increased, while left ventricular end-diastolic pressure (9 +/- 3 vs 5 +/- 3 mmHg (p less than 0.01] and volume index (70 +/- 14 vs 58 +/- 16 ml/m2 (p less than 0.01] decreased. Coronary blood flow and total myocardial oxygen consumption did not change significantly after intervention. As a result, xamoterol enhanced left ventricular external mechanical work versus myocardial oxygen consumption ratio (mechanical efficiency) from 20 +/- 4 to 24 +/- 5% (p less than 0.01). Myocardial oxygen extraction ratio decreased significantly (p less than 0.01) from 66 +/- 5 to 62 +/- 5% after xamoterol. We conclude that xamoterol augments left ventricular mechanical efficiency accompanied by a decrease in coronary vascular tone in patients with normal cardiac function.
Tropical Splenic Lymphoma: Splenic Marginal Zone Lymphoma or Distinct Entity?.
Authors: Elizabeth A. Stephens, Imelda Bates, George Bedu-Addo, Ivy Ekem, Yvonne Dei, Ohene K. Opare-Sem, Sheila J.M. O’Connor, Paul A.S. Evans, Rebecca A. Rollett, Roger G. Owen
Journal: Blood (2006)
It is always the woman who is raped
Authors: D Metzger
Journal: American Journal of Psychiatry (1976)

Rape is described as an act of power that is sanctioned by literature, myth, and culture. Rape is a dire experience for women because it implies total loss of self--the woman is a function, not a person. The victim experiences total emptiness and isolation from self and society. The author believes that an effective "treatment" for the rape victim is community. Women asserting themselves by speaking out about their experience validate themselves as persons.
Epstein-Barr Virus Antigens, Marker Chromosome, and Interferon Production in Clones Derived From Cultured Burkitt Tumor Cells&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Barbara A. Zajac, Gertrude Kohn
Journal: JNCI Journal of the National Cancer Institute (1970)

Clones were obtained from singly seeded lymphoblastoid cells of the EB-2 line of Burkitt's lymphoma origin grown for several days and suspended in medium containing antibodies to the Epstein-Barr virus (EBV). Of the 23 sublines established at a cloning efficiency of over 40%, none differed significantly from the parent culture. They all revealed the C-group marker chromosome (presumably #10), yielded EBV-specific immunofluorescence in 0.1–1% of the cells, and produced small amounts of interferon. Since all clones harbored EBV, despite the fact that the parent culture contained <1% EBV antigen-containing cells, probably the viral genome was present in all cells but prevented from full expression in most of them.
The relation of obesity, body surface area, race and sex with chemotherapy associated toxicity
Authors: T. Armaghany, J. McLarty, J. Marion
Journal: Journal of Clinical Oncology (2008)

22040 Background: Some oncologists reduce the dose of chemotherapy in obese patients (pts) in an attempt to minimize toxicity. Possible overdosing per lean body weight of obese pts has been the rational. This approach may result in under-treatment of some obese individuals. We studied the role of obesity with chemotherapy (CT) associated toxicity. We sub-analyzed the role of race, sex and age as independent factors with CT related toxicity. Methods: We retrospectively analyzed 199 patients (n=83 male), (n = 116 female), (n = 94 white), (n = 105 African American), treated for variety of cancers from 1996–2007. Actual body weight was used to calculate the body surface area (BSA) by the Du Bois formula for CT dosing and the body mass index (BMI) of pts per AGA guidelines. The percent of platelet (plt) drop from base to nadir was chosen as a measure of toxicity. Neutropenia was not chosen as a marker for toxicity, since many pts received growth factor support. All pts received Gemcitabine (GC) as a single agent (n = 91) or in combination with another agent (n = 105). The relation between obesity and changes in plt was assessed by Analysis of Covariance, with race and sex as fixed factors and age, BMI or BSA and GC dose and baseline plt levels as covariates. Results: Using the Analysis of Covariance, no statistically significant relation was found between GC dose and associated toxicity p = 0.32. There was no relation between increased toxicity and increased BMI. p = 0.96. White pts had more toxicity than african americans (p = 0.006). Men had significantly less toxicity (p = 0.033). Age was found to be marginally significant (p = 0.052), with older pts having less toxicity. Baseline plt count was strongly correlated with change in plt counts (p <0.001); higher baseline levels were associated with bigger declines after therapy. A simple linear regression model was able to predict change in plt based upon baseline plt count, sex and race with an adjusted r-squared of 0.725, p <.001. Conclusion: In our study, obesity was not associated with increased toxicity with chemotherapy as measured by percent of platelet change. This study supports full dose treatment of obese patients with chemotherapy. Older patients, males and African Americans had significantly less toxicity at the standard doses. No significant financial relationships to disclose.
Cytology of Rat Liver Cells During Starvation and Refeeding
Authors: T P BHARADWAJ, R LOVE
Journal: JNCI Journal of the National Cancer Institute (1959)

Journal Article Cytology of Rat Liver Cells During Starvation and Refeeding Get access T. P. Bharadwaj, T. P. Bharadwaj Laboratory of Pathology, National Cancer Institute,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert Love Robert Love Laboratory of Pathology, National Cancer Institute,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 23, Issue 4, October 1959, Pages 695–715, https://doi.org/10.1093/jnci/23.4.695 Published: 01 October 1959 Article history Received: 24 March 1959 Published: 01 October 1959
Benefit of thalidomide (THAL) in total therapy 2 (TT2) of multiple myeloma (MM) exhibiting both cytogenetic abnormalities (CA) and low-risk (LR) by gene expression profiling (GEP)
Authors: S. Waheed, J. Shaughnessy, J. Szymonifka, M. Pineda-Roman, K. Hollmig, J. Sawyer, J. Crowley, B. Barlogie
Journal: Journal of Clinical Oncology (2009)

8590 Background: We recently reported an update of TT2 and observed an unexpected preferential benefit from THAL for OS in the subgroup of patients with CA (Blood, 2008). We now re-examined these results with further follow-up of 81 months in the context of GEP-defined risk. Methods: OS and EFS were examined in the 668 patients enrolled in TT2 according to treatment arm, CA status and by GEP risk status. Results: Median overall and event-free survival (OS, EFS) are 9yr and 5yr, with a significant benefit from THAL v the control arm (p=0.04, p=0.0004). We confirmed the ongoing unique survival benefit of THAL in the CA group with 6-yr OS estimates of 53% v 35% (p&lt;0.001), while patients not exhibiting CA had similar OS of 70% and 68%. EFS was superior with THAL regardless of CA status, 56% v 45% without CA (p=0.02) and 38% v 20% with CA (p=0.008). With respect to GEP, THAL benefited the LR group with 6-yr OS/EFS rates of 73%/56% v 63%/36% without THAL (p=0.10/p=0.002); the corresponding data for high-risk (HR) patients showed OS/EFS with THAL of 35%/19% v 15%/10% without THAL (p=0.36/p=0.43). When examined in the context of both GEP and CA, THAL only benefited the 33 patients with both CA and LR with 6-yr OS of 72% v 37% among the 47 without THAL (p=0.003). For the remaining subgroups (CA/HR; no CA/LR, no CA/HR), the addition of THAL did not impact OS. Conclusions: The unique benefit of THAL to the CA/LR subgroup may be linked to its greater efficacy in proliferative MM (enabling CA detection) that can only be sustained in the LR (lacking amplification of 1q21?) but not in the HR subset. The concomitant examinations of MM genetics by both GEP and cytogenetics enabled the discovery of this subgroup-specific treatment benefit. Data on TT3 with the addition of bortezomib will be presented in the context of the CA/GEP-risk scenario. [Table: see text]
Survival of CD23-positive (CD23+) mantle cell lymphoma (MCL) compared to classic CD23-negative (CD23-) MCL: Biologic correlates and clinical outcomes in a 10-year analysis
Authors: A. M. Evens, K. Kelemen, O. Aranha, B. Jovanovic, S. Miyata, B. P. Nelson, C. Goolsby, S. T. Rosen, J. N. Winter, L. C. Peterson, L. I. Gordon
Journal: Journal of Clinical Oncology (2007)

8039 Background: MCL has been historically classified as CD23-, but CD23+ immunophenotype (IP) is identified in a significant minority of patients (pts). It is unclear whether clinicopathologic or survival differences exist between CD23- and CD23+ MCLs. Methods: MCL diagnosis was based on morphology, IP with associated cyclinD1-positivity and/or t(11;14). We identified MCL pts treated at our institution from 1997–2006. We investigated IP (CD23 by flow cytometric analysis), pt characteristics, prognostic factors, and survival. Results: We identified 54 pts (16F/38M), of whom 89% had stage IV disease, IPI = 3 in 57%, 38% elevated LDH, 26% high B2- microglobulin, 30% bulky disease (= 7cm), and 39% with peripheral blood involvement. Thirty-three pts (61%) had CD23- disease, 14 (26%) CD23+ MCL, and 7 (13%) had variable CD23 expression (CD23+/CD23- varied in tissue sites). The only clinicopathologic differences between CD23- and CD23+ pts were increased incidence of extranodal disease (besides marrow or gastrointestinal [GI]) in the former (58% vs. 21%, respectively; p=0.029; most commonly lung or CNS disease); while splenomegaly was more common in the latter (71% vs. 42%; p=0.11). Ki67 staining was not predictive of CD23 status or survival among either IP. Treatment was overall similar in both CD23 groups. Table 1 shows survival for all pts and CD23- pts compared to CD23+ MCL. Cox regression prognostic analysis among all pts (n=54) showed that IPI = 3, bulky disease, and high B2-microglobulin were associated with inferior event-free survival (EFS), while CD23+ MCL and stem cell transplant in first remission were associated with improved EFS (all &lt;0.05). IPI = 3, bulky disease, and presence of extranodal disease besides marrow/GI were associated with inferior overall survival. Conclusions: Over 25% of MCLs are CD23+. CD23+ MCL is associated with a more indolent course and improved outcomes compared with ‘classic‘ CD23- MCL. No significant financial relationships to disclose. [Table: see text]
Phase II study of 21 day continuous intravenous infusion (CIVI) topotecan for recurrent pediatric solid tumors: A Children’s Oncology Group Study (COG A09713)
Authors: S. Bradfield, D. S. Hawkins, J. Whitlock, M. Krailo, J. Franklin, P. C. Adamson
Journal: Journal of Clinical Oncology (2005)

8523 Background: The anti-tumor activity of topotecan is schedule-dependent, with protracted administration having the greatest pre-clinical efficacy. We determined the response rate of selected recurrent pediatric solid tumors to a 21-day CIVI of topotecan. Methods: Patients with Ewing’s sarcoma family of tumors (ESFT), osteosarcoma (OS), soft tissue sarcomas (STS), medulloblastoma (MB)/PNET, astrocytoma, or neuroblastoma (NB) recurrent or refractory to conventional therapy, measurable disease, and adequate organ function were treated with topotecan 0.3 mg/m2/day CIVI for 21 consecutive days, followed by 7 days without therapy prior to response assessment. Courses could be repeated every 28 days. Results: 55 patients were enrolled; two were ineligible, two were removed from protocol therapy prior to evaluation for response, and one was inevaluable for response, leaving 53 and 50 patients evaluable for toxicity and response, respectively. Objective responses were seen in 2/20 patients with ESFT (both partial responses, 3 and 19 courses), 0/10 OS patients, and 0/12 STS patients. There were insufficient patients enrolled to determine the response rate for the MB/PNET, astrocytoma, and NB strata. The most common grade 3 or 4 toxicities during the first course of therapy were thrombocytopenia (12/53), neutropenia (8/53), and fatigue (7/53). Conclusion: Although responses were observed in ESFT, no activity was seen in other sarcoma strata. Further development of prolonged topotecan CIVI for pediatric sarcomas is not warranted. No significant financial relationships to disclose.
ASCO-recommended prognostic factors uPA/PAI-1 in node-negative (N0) breast cancer patients (pts) compared to clinicopathological risk assessment within the NNBC 3-Europe trial
Authors: C. Thomssen, M. Vetter, M. Schmidt, C. Veyret, C. Meisner, G. von Minckwitz, P. Martin, F. C. Sweep, D. Paepke, N. Harbeck
Journal: Journal of Clinical Oncology (2009)

544 Background: ASCO Tumor Marker Guidelines 2007 recommended clinical routine use of the invasion markers uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1 for risk assessment in N0 breast cancer pts (Harris et al, J Clin Oncol. 2007;25:5287). Ten-year follow-up data of the confirmatory prospective clinical uPA/PAI-1 trial (CHEMO-N0) will be presented at the ASCO 2009 Meeting (Harbeck et al.). We conducted a further prospective trial (NNBC 3-Europe) addressing the direct comparison between risk-assessment by uPA/PAI-1 (UP) and clinico-pathological factors (C), and optimization of adjuvant chemotherapy for high-risk N0 pts: FEC*3-Doc*3 vs. standard FEC*6. Methods: From December 2002 to January 2009, 4,040 pts were recruited by 151 centres. For uPA and PAI-1 ELISA, tumors samples were snap frozen und processed. Risk assessment was based on grade and in G2 tumors, either by UP or by a St. Gallen adapted C algorithm. High-risk pts were randomized for adjuvant chemotherapy. All laboratories took part in central quality assurance (QA) for uPA/PAI-1 determination. Results: Risk assessment was performed for 1,590 pts based on C and for 2,445 pts based on UP. End of accrual was planned when 2,572 high risk pts were randomised for chemotherapy and thus ends Jan 31, 2009. Current status shows 1,291 high-risk pts in the FEC-Doc and 1,294 in the FEC arm. In the low-risk arm, 1,450 pts have endocrine therapy, only. By both risk stratifications, 42% of the G2 tumors were assigned as low risk, but in total, more pts were classified as low-risk by UP (39%) than by C (31%). Median uPA level were at 2.40 ng/mg protein (below cutoff), median PAI-1 at 15.9 (above cutoff). In the QA programm, mean coefficients of variations are 12% for uPA and PAI-1 determination. Conclusions: The prospective biomarker trial using uPA/PAI-1 has just ended accrual with more than 4,000 patients. Routine uPA/PAI-1 determination is reliable and feasible even in core needle specimens. Using tumor grade and uPA/PAI-1, adjuvant chemotherapy may be avoided in about 39% of N0 breast cancer pts. Cooperation: EORTC Patho-Biology Group, AGO Breast Group, GBG, Unrestricted grants by Sanofi-Aventis, Pfizer, American Diagnostica, Martin-Luther-Universitaet Halle-Wittenberg. [Table: see text]
Optically guided surgical approach and the outcome of early-stage oral cancers.
Authors: C. F. Poh, J. S. Durham, D. Anderson, K. W. Berean, C. E. MacAulay, L. Zhang, M. P. Rosin
Journal: Journal of Clinical Oncology (2010)

1518 Background: It is becoming increasingly apparent that genetically altered cells are often widespread across the mucosa of oral cancer field, extending into clinically and histologically normal tissue. We have demonstrated that direct fluorescence visualization (FV) technology can detect high-risk molecular and histological change in clinically occult margins and that this could be done in a real-time operating room setting. The objectives of this study were 1) To determine the local recurrence-free survival rate (L-RFS) prior to the implementation of FV in surgery (historical group) and 2) To determine the L-RFS after the implementation of FV in Surgery with the comparison between FV- and non-FV- guided groups. Methods: In consecutive fashions, 168 eligible oral cancer cases were identified: 108 from the BC Provincial Cancer Registry from 2000 to 2003 (Historical group) prior to the implementation of FV in surgery and 60 (32 FV-guided and 28 non-FV guided surgeries) from an on-going longitudinal study (LS group) of the BC Oral Cancer Prevention Program between September 2004 and August 2008. The eligible criteria included oral squamous cell carcinoma with less than 4 cm lesion and with intent-to-cure surgical excision alone. L-RFS was defined as the time from surgery to the development of histologically confirmed disease recurrence of severe dysplasia and above lesions. Results: There was no difference in age, gender, anatomical site and follow-up time between historical and LS groups and between FV- and nonFV- guided groups. While the historical group showed 60% L-RFS (n = 65), LS group showed significantly higher L-RFS (88%, p < 0.0001). Strikingly, all the recurrent cases (n = 7) were in the non-FV guided group (25% vs. 0%, p = 0.003). Conclusions: The implementation of novel FV technology has demonstrated its potential to provide a more effective modality to control local recurrence. The data were collected from a small-sized, single- centred study. In order to further validate this promising result, a multicentric phase III randomized trial across Canada is in its planning phase to examine the efficacy of this optical technology. Supported by R01 DE17013 from NIH/NIDCR and CCSRI-20336 from Canadian Cancer Society Research Institute. No significant financial relationships to disclose.
Long-term survival and disease regression after adrenalectomy for adrenal metastases from melanoma
Authors: F. Collinson, W. De Bruijn, M. Lamont, R. Kefford, J. De Wilt, J. Thompson
Journal: Journal of Clinical Oncology (2004)

7540 Background: Human melanoma cells express high affinity glucocorticoid receptors, and adrenalectomy has been shown to have anti-melanoma effects in animal models. We observed long-term regression of metastatic melanoma in two patients following bilateral adrenalectomy, prompting a review of adrenalectomy at the Sydney Melanoma Unit (SMU). Methods: All SMU patients having adrenalectomy for melanoma metastatic to the adrenal gland(s) between January 1987 and June 2001 were identified and examined. Results: 17 patients underwent adrenalectomy for adrenal metastases, 5 females and 12 males, median age 62 years. The adrenal gland(s) were the sole site of disease in 13 patients. Indications were pain (n=4), or the detection of bulky metastases on radiological imaging (n=13). Five patients had bilateral adrenal metastases resected. Significant post-operative morbidity occurred in 2 patients (12%), but there was no post-operative mortality. The median survival of patients after adrenalectomy was 19 months (2 year survival 46%), compared with 4 months for patients with documented adrenal metastases concurrently treated with best supportive care (n=127) (p=0.0001). In two patients non-resected metastases elsewhere regressed following bilateral adrenalectomy, and both remain disease free over three years later. Conclusion: As previously reported, adrenalectomy for adrenal melanoma metastases is associated with prolonged survival in selected patients. We report for the first time sustained complete regression of distant metastatic melanoma following adrenalectomy, suggesting a possible role for adrenal hormones in modifying melanoma in certain patients. No significant financial relationships to disclose.